Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | CLL updates from ASH 2018: ibrutinib is the treatment of choice

John Gribben • 2 Jan 2019
ASH 2018
Chronic Lymphocytic Leukemia Leukemia Bendamustine Obinutuzumab Rituximab Venetoclax
ALLIANCE A041202 ECOG-E1912 iLLUMINATE MURANO

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of the Barts Cancer Institute, London, UK, provides an overview of key updates in treatment for chronic lymphocytic leukemia (CLL), specifically the ECOG-E1912 (NCT02048813), MURANO (NCT02005471), and iLLUMINATE (NCT02264574) studies investigating ibrutinib alone or in combination with monoclonal antibodies vs. FCR – the standard chemoimmunotherapy treatment. Prof. Gribben was speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from John Gribben

2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
3:31
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals